US ITC bars imports of low-cost Botox amid trade secrets dispute
The US International Trade Commission (ITC) has sided in favour of AbbVie/Allergan, which argued that a rival should be prevented from importing a low-cost version of its Botox treatment into the US for 21 months, because it had stolen trade secrets.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
4 March 2019 The US International Trade Commission has begun an investigation into Daewoong Pharmaceuticals of South Korea and California-based Evolus, following a complaint from Allergan.